The Health Insurance Fund is expanding the list of drugs it covers at its own expense, and director Saso Klekovski came out to clear up the questions around the expanded positive list. Among the new drugs entering Fund coverage from July are Clexane and Fraxiparine - preparations for preventing blood clotting.

For patients who use these drugs, the news is concrete and good: what they used to pay out of pocket is now at least partly covered by insurance. For therapies taken long-term, the difference between "covered by the Fund" and "out of your own pocket" can mean hundreds of euros a year - money that for many families is not small.

But every expansion of the list also raises questions. Which drugs get in, and which stay out? By what criteria is it decided? And what about patients whose therapies are still not on the list, even though they are vital? The positive list is one of the most direct links between the state and a citizen's health - and that is exactly why every change to it deserves attention, not just an announcement.

The healthcare system in the country has struggled with the same problems for years - drug shortages, waiting, unequal access. Expanding the list is a step forward, and that should be acknowledged. But the real test is not how many drugs get added at a press conference, but whether the patient actually finds their medicine at the pharmacy when they need it. Promises are easy. A full medicine cabinet is heavier.